secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2026-04-01T23:59:59+00:00
Accession:  0001193125-26-137909
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 5.01, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion to merge with Korsana in reverse merger; $380M PIPE; CVRs for legacy assets
--------------------------------------------------------------------------------

- Merger: pre-Merger Korsana stockholders own ~1.5% of combined co (pre-PIPE); Cyclerion shareholders ~98.5%.
- $380M PIPE into Korsana led by institutional investors concurrent with merger.
- Pre-merger Cyclerion shareholders get CVRs for future proceeds from Akebia license, Tisento stock, and other legacy assets.
- Combined co board of 6 all Korsana designees; CEO to be Korsana's president and CEO.
- Merger expected to close Q3 2026; subject to Cyclerion shareholder vote, HSR, Nasdaq approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000119312526137909/0001193125-26-137909-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000119312526137909/d128275d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-137909

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer